Reach your audience. Get results.
Rely on the experience, guidance, and superior media targeting of Business Wire for your global press release distribution.
Public RelationsMaximize the reach of your news with our press release distribution services and partnerships. Investor RelationsReach and engage investors, shareholders, analysts, and media with our complete suite of IR services and tools. Distribution & AnalyticsTarget your news, reach your audiences, and understand the impact of your press releases with our analytics reports. |
Latest News
Today is June 03, 2024.
All times in Eastern Daylight Time.
-
TotalEnergies : Déclaration des Transactions sur Actions PropresPARIS--(BUSINESS WIRE)--Regulatory News: Dans le cadre des autorisations consenties par l’Assemblée générale du 24 mai 2024 pour opérer sur ses actions et conformément à la réglementation relative ... more »
-
TotalEnergies: Disclosure of Transactions in Own SharesPARIS--(BUSINESS WIRE)--Regulatory News: In accordance with the authorizations given by the shareholders’ general meeting on May 24,2024, to trade on its shares and pursuant to applicable law on sh... more »
-
PARIS--(BUSINESS WIRE)-- In accordance with the authorizations given by the shareholders’ general meeting on May 24,2024, to trade on its shares and pursuant to applicable law on share repurchase,... more »
-
PUTEAUX, France--(BUSINESS WIRE)--Regulatory News: emeis (Paris:ORP) announces that it has signed a sale and lease back agreement on a real estate portfolio of three nursing homes in Ireland with H... more »
-
PUTEAUX, France--(BUSINESS WIRE)--Regulatory News: emeis (Paris:ORP) annonce la signature d'un accord de cession et prise à bail portant sur un portefeuille immobilier de trois maisons de retraite ... more »
-
OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent OsteosarcomaROCKVILLE, Md.--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic ... more »
-
PARIS--(BUSINESS WIRE)--Regulatory News: Vivendi (Paris:VIV) : Place de cotation : NYSE Euronext-Paris Compartiment : Eurolist A Code ISIN : FR0000127771 Date Nombre total d’actions composant le ca... more »
-
Susan Michaels Joins Presidio Investors as Operating PartnerAUSTIN, Texas--(BUSINESS WIRE)--Presidio Investors, a leading investment firm specializing in high-growth companies, is pleased to announce the appointment of Susan Michaels as Operating Partner, e... more »
-
Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for May 2024, includes Reg.-NMS Execution StatisticsGREENWICH, Conn.--(BUSINESS WIRE)--Interactive Brokers Group, Inc. (Nasdaq: IBKR) an automated global electronic broker, today reported its Electronic Brokerage monthly performance metrics for May.... more »
-
PARIS & LONDON & NEW YORK--(BUSINESS WIRE)--Regulatory News: Antin Infrastructure Partners (Paris:ANTIN): Date 31 May 2024 Company name Antin Infrastructure Partners Trading place Euronext Paris (c... more »
-
Lucent Health Introduces Quantify Specialty Care Program, Designed to Provide Patient-Centric, Lower Cost Infusion CareNASHVILLE, Tenn.--(BUSINESS WIRE)--Lucent Health is proud to announce Quantify Specialty Care, a new program designed for patients who require specialty drug infusions. more »
-
Battelle and Allonnia to Co-Host 2025 Bioremediation and Environmental Biotechnology ConferenceCOLUMBUS, Ohio--(BUSINESS WIRE)--Battelle is pleased to announce that it will co-host the Seventh International Symposium on Bioremediation and Environmental Biotechnology with Allonnia. The event ... more »
-
Das Krankenhaus Germans Trias i Pujol in Spanien führt ein Programm für Telemedizin und Fernbetreuung von Patienten mit Masimo W1 ® Medizinische Uhren und Radius VSM™ Tragbare Monitoren für die kontinuierliche Überwachung der Vitalparameter einBARCELONA, Spanien--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) gab heute bekannt, dass Germans Trias i Pujol, ein Pionierkrankenhaus im Norden Barcelonas, das mehr als 800.000 Menschen versorgt, eine b... more »
-
Acticor Biotech Updates Its Glenzocimab Clinical Development Plan for the Treatment of Cardiovascular EmergenciesPARIS--(BUSINESS WIRE)--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovas... more »
-
Acticor Biotech fait le point sur le plan de développement clinique du glenzocimab dans le traitement des urgences cardio-vasculairesPARIS--(BUSINESS WIRE)--Regulatory News : ACTICOR BIOTECH (FR0014005OJ5 - ALACT), société de biopharmaceutique au stade clinique spécialisée dans le développement de médicaments innovants pour le t... more »